Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316028 | 1.00 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL29861722 | 1.00 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL17129221 | 0.90 | SMN1; SMN2 (0.44) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL1553366 | 0.87 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL2011966 | 0.87 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL24298740 | 0.85 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL2434610 | 0.85 | CTSS (0.45) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL16363856 | 0.85 | CTSS (0.45) | NPC1RAB9ASMN1; SMN2LMNABCAT2 | |
| SCHEMBL3657534 | 0.85 | GAA (0.48) | NPC1RAB9ASMN1; SMN2LMNASYK | |
| SCHEMBL17373694 | 0.85 | AAK1 (0.47) | NPC1RAB9ASMN1; SMN2LMNAAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741423-A2 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Mablink Bioscience (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4713020-A2 | DRUG-LINKERS AND DRUG CONJUGATES | Solve Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121586589-A | Drug linkers and drug conjugates | 索尔夫治疗公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | SOLVE THERAPEUTICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2025227010-A1 | PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ELI LILLY AND COMPANY (US) | 2025-10-30 | — | — | WO | disclosed |
| US-20250302978-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | MABLINK BIOSCIENCE (FR) | 2025-10-02 | — | — | US | disclosed |
| EP-4489788-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Mablink Bioscience (FR) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024243085-A2 | CONJUGATES AND USES THEREOF | SOLVE THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240216525-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | MABLINK BIOSCIENCE (FR) | 2024-07-04 | — | — | US | disclosed |
| EP-4313157-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | Mablink Bioscience (FR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023170247-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | MABLINK BIOSCIENCE (FR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022207699-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | MABLINK BIOSCIENCE (FR) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216525-A1 | ENZYME-TRIGGERED SELF-REACTING LINKER HAVING IMPROVED PHYSICOCHEMICAL AND PHARMACOLOGICAL PROPERTIES | DDC, BCHE, ENGASE | NPC1 4094/4885RAB9A 3843/4885SMN1; SMN2 3126/4885 |
| US-20260007762-A1 | ANTI-ROR2 ANTIBODY-DRUG CONJUGATES | RORB, RORA, RORC | NPC1 1234/4885RAB9A 2536/4885SMN1; SMN2 1543/4885 |
| US-20250302978-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | FOLR1, FOLR2, FCGR2A | NPC1 2066/4885RAB9A 1673/4885SMN1; SMN2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.